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Abstract
Background: Left ventricular (LV) remodeling is closely linked to the progression of heart failure. There are limited
data on the epidemiology of new onset LV remodeling among elderly women, which requires further investigation.
Method: We examined data from a community-based cohort of women aged > 65 years, who had received > 2
echocardiography scans from 2009 to 2014. Exclusion criteria for patients included prior echocardiographic
evidence of left ventricular enlargement (LVE) or hypertrophy (LVH). LVE was defined as the index of left ventricular
internal diameter at end-diastole to height, and LVH was defined as the left ventricular mass and thickness index
which indicate hypertrophy.
Results: Of the 474 subjects (age 71.85 ± 6.47 years), 49 (10.3%) developed LVH, while 55 (11.6%) developed LVE
during the mean follow-up period of 5 years. Independent predictors of LVH included: central blood pressure
(CBP, per 10 mmHg) [HR 1.094, 95% CI 1.011–1.202], BMI˃25(kg/m 2)[HR 1.306, 95% CI 1.175–1.434], B-type natriuretic
peptide (BNP) ≥ 100 (pg/mL) [HR 1.635, 95% CI 1.107–3.311] and brachial-ankle pulse wave velocity (baPWV) ≥16
m/s [HR 1.605, 95% CI 1.474–2.039]. Predictors of LVE were CBP (per 10 mmHg) [HR 1.121, 95% CI 1.027–1.238],
BMI˃25(kg/m 2)[HR 1.302, 95% CI 1.173–1.444], Low-density lipoprotein cholesterol (LDL-C) [HR 1.193, 95%CI 1.013–1.
405] and E/e’ ratio [HR 1.077, 95% CI 1.017–1.140].
Conclusion: CBP and BMI were demonstrated to be independent and robust predictors of left ventricular remodeling
among elderly women, including both LVE and LVH. BNP and baPWV were specifically related to the development of
LVH, whereas LDL-C and E/e’ ratio were related to LVE.
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Background
Left ventricular (LV) remodeling is considered as a pre-
cursor for worsening cardiac function and is often asso-
ciated with a high mortality rate in affected patients [1].
Studies have suggested that patients usually progress
through an adverse LV remodeling phase prior to devel-
opment of symptomatic heart failure (HF) [2]. Substan-
tial progress has been made in improving the accuracy
and early assessment of LV remodeling. However, identi-
fication of the early predictors of LV remodeling as well
as their potential roles is still poorly understood. Re-
cently, several longitudinal cohort studies have identified
the importance of chronic non-cardiac diseases which
may result in the progression and deterioration of sub-
clinical LV remodeling to HF [3, 4].
Numerous studies support the notion that males are
significantly more at risk in the development of cardio-
vascular events. A potential underlying mechanism may
be closely related to the protective effect of estrogen ex-
pression in women [5]. In the elderly population, the
prevalence of HF is indistinguishable between males and
females [6]. It is noteworthy that women are more
prone to have increased relative wall thickness [7].
However, epidemiological data on the prevalence of LV
remodeling risk factors and their impact in women are
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still unclear. Therefore, it is important to acquire data
from population-based studies on women with LV re-
modeling, including incidences of LVE and LVH.
There are limited studies which examine the relationship
between various bio-markers and central hemodynamic
indexes with the specific type of LV remodeling. Our
previous study demonstrated that women have double
the incidence rate of LV remodeling compared to
men [8]. Therefore, the current cohort study con-
sisted of 474 elderly women subjects. This study




The baseline examination was carried out in 2009. All
the participants underwent physical examination, struc-
tured interview, blood sampling, and pulse wave analysis
at the research center, as well as an echocardiography
scan [8]. A total 1259 women (age>18) were randomly
recruited from the Lujiazui community, Shanghai, China.
1070 of them underwent follow-up investigation in 2014.
For the present study, we aimed to investigate the pre-
dictors of new-onset LV remodeling among elderly
women. According to the exclusion criteria: 305 were
excluded for their age less than 65 year; 93 were excluded
for their medical history of Coronary heart disease (CHD),
Heart failure (HF) and Valvular heart disease (VHD). The
198 subjects who were diagnosed as LV remodeling prior
to cohort entry were also excluded. As a result, 474 sub-
jects were eligible for the current study. During the 5 year
follow up period, 45 women had developed LVH and 55
had developed LVE. Detailed information of the study
population is provided in Fig. 1.
Echocardiographic analysis
Echocardiography examination with trans-thoracic two-
dimensional (2D) scanning was performed using a color
Doppler ultrasonic device equipped with a 1.0–5.0 MHz
transducer (GE Vivid 7; General Motors Corporation,
New York, USA). Cardiac parameters including left
atrium diameter (LAD), left ventricular internal diameter
at end-diastole (LVIDd), left ventricular ejection fraction
(LVEF), inter ventricular sepal thickness (IVST) and pos-
terior left ventricular wall thickness (PVWT) were col-
lected based on echocardiographic examination. E/A ratio
was calculated based on peak early diastolic flow velocity
(E velocity)/peak velocity of atrial contraction (A velocity).
E/e’ ratio was determined by the E velocity/velocity of mi-
tral annulus early diastolic motion (e’).
Defining left ventricular enlargement and hypertrophy
We have previously reported the methodology for defin-
ing LVH and LVE in a cross-sectional study [8]. Thus,
we used these former standards for the follow-up assess-
ment. Preliminary criteria for defining LVH depended
on the measurement of left ventricular mass index
(LVMi). LVMi was determined by dividing the LVM
measurement by height2.71. LVM was calculated based
on the guidelines from the American Society of Echocar-
diography: LVM (g) = 0.8 × {1.04 × [(LVIDd + PVWT +
IVST) 3− (LVIDd) 3]} + 0.6 (g) [9]. LVH was defined as
LVMi > 46.7g/m2.71 for women and LVE was determined
by indexing LVIDd to height, as previously demonstrated
[10]. LVE was defined by LVIDd (mm) of greater than
28.3 + [13.9 × height (m)] for women [10].
Laboratory measurements
All blood samples were obtained during the morning fast-
ing state. Plasma total cholesterol (TC), high-density lipo-
protein cholesterol (HDL-C), triglycerides (TG) and Fasting
plasma glucose (FPG) were measured enzymatically. Brain
natriuretic peptide (BNP, ECLIA Roche Diagnostics, Mann-
heim, Germany) was measured using electro chemilumin-
escence immunoassay. Glaciated hemoglobin (HbA1C) was
measured using ion-exchange high performance liquid
chromatography. Serum high-sensitivity C reactive protein
(hsCRP) was measured using immunonephelometry (Dade
Behring Diagnostics, Marburg, Germany). Homocysteine
(HCY) was measured using fluorescence polarization im-
munoassay (Abbott IMx System, Chicago, IL, USA). Dia-
betes was defined as fasting plasma glucose (FPG)
levels ≥7.0mmol/L, or self-reported diagnosis of dia-
betes. Dyslipidemia was defined as total cholesterol
(TC) >5.7 mmol/L or low-density lipoprotein choles-
terol (LDL-C) >3.6 mmol/L.
Fig. 1 Flowchart of the study. LVH, left ventricular hypertrophy; LVE,
left ventricular enlargement; CAD, coronary artery disease; HF, heart
failure; VHD, valvular heart disease
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Pulse wave analysis
Non-invasive pulse wave analysis was performed with an
automated oscillometric device (HEM-9000 AI; Omron
Corp., Tokyo, Japan). Subjects were examined in a sitting
posture. Radial augmentation index (AI), Systolic blood
pressure(SBP), diastolic blood pressure (DBP), and esti-
mate of central blood pressure (CBP) were obtained
after resting for 5–10 min. Hypertension was defined as
either systolic blood pressure (SBP) ≥140 mmHg, dia-
stolic blood pressure (DBP) ≥90 mmHg, or usage of an-
tihypertensive medication. The detailed methodology
was validated in our previous report [8].
Brachial-ankle pulse wave velocity measurement
baPWV was measured using a volume-plethysmographic
device (PWV/ABI, Omron Corp., Tokyo, Japan), which
simultaneously recorded brachial and posterior tibial ar-
terial wave forms with automated oscillometric method
[11]. Echocardiographic examination was performed by
placement of electrodes on the wrists and cuffs on the
bilateral brachia and ankles of subjects, while resting in
a supine position. The average value of baPWV was
taken if there were differences in the measurements
from the left and right sides [12].
Statistical analysis
SPSS 19.0 (SPSS, Inc., Chicago, IL, USA) was used for
statistical analysis. Categorical variables were presented as
frequency percentages and the comparison between
groups were based on the chi-squared test. Continuous
variables were presented as means and standard deviation
(SD) for normal distribution. Two samples T-test was used
to compare differences between groups. We described
skewed distribution variables as median (inter-quartile
range). Accordingly, these variables were compared by
nonparametric Mann-Whitney U-test. Multivariate cox
proportional hazards regression models were developed to
assess independent predictive value of LVE or LVH. A
value of p<0.05 was considered statistically significant.
Results
The baseline characteristics of the study population and
patients with LVH or LVE are summarized in Tables 1
and 2. The average age of the 474 participants were
71.85±6.47 years, and had no prior history of heart dis-
eases and echocardiographic evidence of LVH and LVE.
Over a mean follow-up period of 5 years, 49 (10.3%)
subjects had developed LVH; 55 (11.6%) subjects had de-
veloped LVE; 22 (4.6%) subjects had both LVH and LVE.
Comparison between patients with or without LVH at
baseline indicated that the level of BMI, CBP, baPWV
and hsCRP in patients with LVH was significantly higher
than that in those without LVH (P <0.05 for all). A simi-
lar result was observed in patients with or without LVE.
Of note, increased BNP level was only found in subjects
with LVH. Patients with LVE had higher age and were
prone to have increased levels of LDL-C. Cardiac ultra-
sonography parameters between these groups are dis-
played in Table 2. Owing to the echocardiographic
definitions for LVE and LVH, both groups had higher
left ventricular geometry parameters. Subjects with LVE
were also observed to have higher E/e’ ratio.
The multivariate models were developed to predict the
first events of LVH and LVE. We selected variables that
demonstrated significant statistical differences between
groups (LVH vs. non-LVH, and LVE vs. non-LVE) and
those variables were entered into multivariate Cox regres-
sion models for the assessment of independent risk factors
of LVH or LVE. As shown in Table 3, CBP (per 10mmHg;
HR 1.094; 95%CI 1.011–1.202), BMI 25(kg/m 2) (HR
1.336; 95%CI 1.195–1.494), BNP ≥ 100 (pg/mL) (HR 1.635;
95%CI 1.107–3.311) and baPWV ≥16 (m/s) (HR 1.605;
95%CI 1.474–2.039) were associated with the develop-
ment of LVH. Independent predictors of LVE included
CBP (per 10mmHg; HR 1.121; 95%CI 1.027–1.238),
BMI 25(kg/m 2) (HR 1.302; 95%CI 1.173–1.444), LDL-C
(HR 1.193; 95%CI 1.013–1.405) and E/e’ ratio (HR, 1.077;
95%CI 1.017–1.140), as demonstrated in Table 4.
Discussion
In this longitudinal cohort study among elderly women,
there was a high incidence of new-onset LVE (11.6%)
and LVH (10.3%) occurrence. The increase in the levels
of CBP and BMI were predictive for both LVE and LVH,
after accounting for various potential confounding fac-
tors. BaPWV index using detailed noninvasive evaluation
and BNP were specifically correlated with the develop-
ment of LVH, but not LVE. In addition, the E/e’ ratio
using Doppler echocardiogram and LDL-C were predict-
ive for the development of LVE.
The effect of gender during cardiac remodeling is still
unclear. Data from Framingham Heart Study revealed
that women have a greater age-related increase in LV
wall thickness [13]. It has also been reported that
concentric remodeling is more pronounced in women
[14, 15]. To our knowledge, our study is the first which
examines the predictors of LV remodeling among elderly
women. We had previously reported that among women
(age > 40 years), the prevalence of LVH and LVE were
9.34% and 10.04%, respectively [8]. Our current findings
show a relatively high incidence rate for both LVH and
LVE in elderly women. This could be partly due to the
changes in hormone levels in post-menopause women.
The cardio-protective role of estrogen has been well
established. However, the high prevalence of LVH and
LVE might not be entirely due to the depletion of estro-
gen, but also the expression of testosterone, which pro-
motes cardiac dysfunction and remodeling [16]. Studies
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Table 2 Baseline echocardiographic characteristics of study population according to left ventricular remodeling status at follow up
(left ventricular hypertrophy vs. non-left ventricular hypertrophy, left ventricular enlargement vs. non-left ventricular enlargement)
Characteristic All subjects
(n = 474)
Groups P-value Groups P-value
LVH (n = 49) Non-LVH (n = 425) LVE (n = 55) Non-LVE (n = 419)
LVMI (g/m2.71) 35.91 (30.41, 41.36) 51.42 (48.42, 56.53) 34.79 (30.09, 39.51) 0.000 47.21 (40.10, 55.12) 34.87 (30.0, 39.67) 0.000
LVM (g) 12 176.19±21.29 122.81±25.18 0.000 160.31±17.26 124.10±23.77 0.000
RWT 0.35±0.05 0.36±0.05 0.34±0.04 0.133 0.30±0.04 0.35±0.05 0.000
LVEF (%) 64.44±3.51 62.83±3.01 63.51±3.57 0.135 63.78±3.36 64.53±3.51 0.124
E/e’ ratio 12.5 (9.09, 16.6) 14.28 (11.11, 18.0) 12.5 (9.09, 16.66) 0.080 13.46 (11.5, 16.6) 12.5 (8.33, 16.6) 0.019
E/A ratio 1.12±0.32 1.02±0.18 1.12±0.24 0.088 0.96±0.22 1.14±0.16 0.127
LAD (mm) 34.73±5.41 36.31±3.81 34.50±5.51 0.006 36.71±4.56 34.46±5.64 0.003
LVIDd (mm) 46.66±4.13 50.73±3.79 46.17±3.89 0.000 52.62±2.70 45.86±3.61 0.000
PVWT (mm) 8.05±1.06 8.98±1.30 7.03±0.98 0.000 8.05±1.27 8.01±1.02 0.670
IVST (mm) 8.56±1.24 10.08±1.26 8.38±1.11 0.000 8.97±1.57 8.11±1.17 0.036
Continuous variables with normal distribution were expressed as the mean±SD. In case of skewed distribution continuous variables (containing LVMI and E/e’)
were presented as median (inter-quartile range)
LVH left ventricular hypertrophy, LVE left ventricular enlargement, LAD left atrium diameter, LVEF left ventricular ejection fraction, LVMI left ventricle mass index,
LVIDd left atrium diameter, left ventricular internal diameter at end-diastole, IVST inter ventricular sepal thickness, PVWT posterior left ventricular wall thickness
Table 1 Baseline clinical characteristics of study population according to left ventricular remodeling status at follow up (left
ventricular hypertrophy vs. non-left ventricular hypertrophy, left ventricular enlargement vs. non-left ventricular enlargement)
Characteristic All subjects
(n = 474)
Groups P-value Groups P-value
LVH (n = 49) Non-LVH (n = 425) LVE (n = 55) Non-LVE (n = 419)
Age (years) 71.85±6.47 72.39±6.54 71.80±6.49 0.148 72.88±6.27 71.74±6.48 0.046
BMI (kg/m2) 24.35±3.18 27.08±3.47 24.03±2.98 0.000 26.95±3.72 24.00±2.93 0.000
SBP (mmHg) 138.85±20.50 151.02±19.61 137.39±20.12 0.000 150.25±20.80 137.37±20.01 0.000
DBP (mmHg) 76.49±11.20 81.67±9.15 75.79±11.14 0.000 81.82±10.35 75.80±11.44 0.000
CBP (mmHg) 144.35±22.30 157.13±21.28 142.93±19.80 0.000 157.05±24.34 142.70±21.51 0.000
baPWV (cm/s) 16.32 (14.42, 18.67) 17.47 (14.93, 20.53) 15.21 (13.98, 18.44) 0.000 17.10 (15.13, 19.73) 16.21 (14.31, 17.98) 0.028
Hypertension 205 (43.2%) 29 (59.2%) 176 (41.4%) 0.022 31 (56.4%) 174 (41.5%) 0.058
Diabetes 48 (10.1%) 6 (12.2%) 42 (9.9%) 0.514 7 (12.7%) 41 (9.8%) 0.281
Dyslipidemia 121 (25.2%) 13 (26.5%) 108 (25.4%) 0.865 18 (32.7%) 103 (24.6%) 0.237
Laboratory tests
TC (mmol/l) 5.31±0.96 5.37±1.06 5.30±0.95 0.820 5.30±1.07 5.31±0.95 0.964
TG (mmol/l) 1.77±0.39 1.82±0.23 1.77±0.41 0.750 1.87±0.64 1.76±0.58 0.479
HDL-C (mmol/l) 1.32±0.32 1.31±0.35 1.32±0.31 0.802 1.27±0.29 1.32±0.32 0.212
LDL-C (mmol/l) 3.28±0.75 3.24±0.63 3.28±0.56 0.758 3.72±0.70 3.22±0.83 0.015
FPG (mmol/l) 5.39±1.01 5.59±0.78 5.37±0.96 0.249 5.53±0.66 5.37±0.41 0.337
HbA1C (%) 5.98±0.98 5.92±0.56 5.99±1.01 0.553 6.08±0.54 5.88±0.79 0.169
BNP (pg/ml) 60.0 (35.0, 95.0) 75.0 (40.0, 133.0) 60.0 (35.0, 91.5) 0.016 70.0 (42.0, 123.0) 60.0 (35.0, 93.5) 0.254
HCY (umol/l) 11.0 (9.5, 14.0) 12.0 (10.0,14.0) 11.0 (9.0, 14.0) 0.354 11.0 (9.0, 14.0) 11.0 (9.0, 13.5) 0.750
hsCRP (mg/l) 1.35 (0.69, 2.59) 1.98 (0.99, 3.27) 1.31 (0.68, 2.51) 0.019 1.97 (0.99, 3.86) 1.30 (0.67, 2.34) 0.004
UA (umol/l) 310.0 (263.5, 361.5) 323.0 (286.0, 346.0) 309.0 (263.0, 363.0) 0.207 308.0 (268.0, 365.0) 310.0 (264.0, 361.0) 0.745
Continuous variables with normal distribution were expressed as the mean±SD. In case of skewed distribution continuous variables (containing baPWV, BNP, HCY,
hsCRP, UA) were presented as median (inter-quartile range)
BMI body mass index, BNP B-type natriuretic peptide, DBP diastolic blood pressure, FPG fasting plasma glucose, LVH left ventricular hypertrophy, LVE left ventricular
enlargement, HCY homocysteine, HDL-C high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein, LDL-C low-density lipoprotein cholesterol,
SBP systolic blood pressure, TC total cholesterol, TG total triglycerides
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have demonstrated that women are less likely to receive
preventive treatment or guidance, such as lipid-lowering
drugs, aspirin, and therapeutic lifestyle changes [17]. Thus,
inadequate control of risk factors in women is a potential
risk factor for the occurrence of LV remodeling.
Increased BMI and BP are commonly recognized as
predictors of cardiovascular disease. Our study further
strengthened the notion that BMI and CBP were the im-
portant predictors of LV remodeling, and were strongly
related to the development of both LVH and LVE. These
findings suggest that effective control of body weight
and BP are crucial in the early prevention of LV remod-
eling. We had previously reported that BNP was a risk
factor for both LVH and LVE in the general population
[8]. However, our current regression model showed that
BNP failed to independently predict for LVE. BNP is ele-
vated in response to an increase in myocardial wall
stress. Early mild ventricular dilation plays a protective
role and helps maintain an adequate stroke volume [18].
Therefore, this cardiac compensatory function would
not lead to significant increases in BNP level following
development of LVE. Due to the difference in study
population, this result may be explained in part by the
gender-specific control of myocardial adaptations to
hemodynamic overload. To support this notion, studies
have revealed a rapid induction of plasma BNP and ANP
during myocardial dysfunction in men [19].
Dyslipidemia is the metabolic abnormalities observed
frequently in patients with heart diseases. Francesco et al
reported that unsatisfactory control of LDL cholesterol
after myocardial infarction independently predicts LV re-
modeling [20]. For the current study, we found that high
LDL-C predicted the development of left ventricular en-
largement, but not hypertrophy in multivariable models.
Due to the limited data on the relationship between
LDL-C and left ventricular remodeling, it is still different
to tell whether high LDL-C specifically predicts LVE.
This result is broadly consistent with the findings of
previous researches [20, 21]. Also, in some sense, it
strengthens the need for the achievement and mainten-
ance of target serum lipids for reducing LV remodeling.
The ratio of early trans-mitral flow velocity (E) to early
diastolic septal mitral annulus velocity (E/e’) has been
shown to be the most accurate noninvasive predictor of
elevated LV filling pressure [22]. According to the
echocardiography-Doppler criteria for assessment of dia-
stolic function, E/e’>10 indicate moderate to severe dia-
stolic dysfunction [23]. During pressure overload, hearts
of female subjects often develop concentric hypertrophy
as a compensatory function in order to maintain stable
cardiac function [18]. However, when the impairment
progresses past a certain stage, ventricular dilation takes
place. Our results demonstrated that E/e’ was a pre-
dictor of LVE in elderly female subjects. These patients
often do not report adverse symptoms, however they are
at risk to more serious deterioration of cardiac function.
Whether E/e’ and LVIDd is directly proportional is still
unknown, and requires further investigation.
Cardiac abnormalities in adults often develop in concert
with atherosclerosis [24]. BaPWV is a promising tech-
nique to assess arterial stiffness in large population-based
investigations [25]. Numerous studies have reported a
positive correlation between increased LVMI and baPWV
[26, 27]. Arterial stiffness may contribute to LVH inde-
pendently of BP [26, 28]. Our current study showed that
risk of LVH rose markedly in patients with baPWV>16m/
s. Increased vascular resistance with hypertension places
severe strain on the heart, which is by far the most com-
mon cause of LVH [29]. High baPWV level is a common
sign of atherosclerotic vascular damage. Thus, evaluation
of baPWV is particularly important in elderly women, as a
convenient and early indicator of LVH.
This study has several limitations that need to be ad-
dressed. Firstly, the prevalence of LVH and LVE might
Table 4 Multivariate model for prediction of LVE
Variables Hazard Ratio 95%
Age (years) 1.012 0.962–1.066 0.338
Hypertension (%) 1.282 0.725–2.888 0.550
CBP (per 10mmHg) 1.121 1.027–1.238 0.004
BMI ≥25 (kg/m2) 1.302 1.173–1.444 <0.001
LDL-C 1.193 1.013–1.405 0.034
hsCRP (mg/L) 1.068 0.967–1.180 0.195
baPWV ≥16 (m/s) 1.573 0.869–2.568 0.159
E/e’ ratio 1.077 1.017–1.140 0.011
Values expressed as Hazard Ratio and 95% confidence interval (CI).
Abbreviations are the same as in Tables 1 and 2
Covariates in the basic model included age, hypertension, CBP, BMI ≥25
(kg/m2), LDL-C, hsCRP, baPWV ≥16 (m/s) and E/e’ ratio
Table 3 Multivariate model for prediction of LVH
Variables Hazard Ratio 95%
Age (years) 1.032 0.912–1.108 0.248
Hypertension (%) 1.233 0.610–2.491 0.560
CBP (per 10mmHg) 1.094 1.011–1.202 0.021
BMI ≥25 (kg/m2)a 1.306 1.175–1.434 <0.001
BNP ≥100 (pg/mL)b 1.635 1.107–3.311 0.007
hsCRP (mg/L) 1.009 0.771–1.123 0.664
baPWV ≥16 (m/s) 1.605 1.474–2.039 0.009
Values expressed as Hazard Ratio and 95% confidence interval (CI).
Abbreviations are the same as in Table 1
Covariates in the basic model included age, hypertension, CBP, BMI ≥25 (kg/m2),
BNP ≥ 100 (pg/mL), hsCRP and baPWV ≥16 (m/s)
aBMI greater than 25 is considered overweight and formed into two categories
according to NICE Guidance 2014
bBNP was formed into two categories according to European Society of
Cardiology Guidelines for the diagnosis and treatment of acute and chronic
heart failure 2012
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be overstated since the use of echocardiography as a
routine screening strategy for cardiac remodeling in
population-based investigation remains controversial. LV
mass calculated according to the measurements of echo-
cardiography may be overestimated when compared
with the gold standard of MRI [30]. Echocardiography is
now listed as a class I evidence for the evaluation of pa-
tients with HF, while also being widely used for observ-
ing alterations in LV geometry and structure [7, 9].
Considering the convenience and practicability of echo-
cardiography in population-based epidemiological inves-
tigations, it is the preferred choice for our research
design. Secondly, in order to avoid potential bias of in-
formation obtained from the self-administered question-
naire, we did not analyze effects of drug use and
postpartum hemodynamic changes which may poten-
tially influence LV geometry. The data presented herein
were grouped as the presence or absence of LVE (and
LVH). Eighteen subjects were confirmed with both LVE
and LVH according to the assessment criteria. We fell
short of a combinatorial assessment these two remodel-
ing patterns. This needs to be compensated in our future
investigations.
Conclusion
This study shows the incidence rates of new onset LV
remodeling in a community-based nested case-control
cohort. Risk profiles at baseline for LVH and LVE were
determined. We determined that increased LV remodel-
ing may be associated with higher incidence of HF with
preserved ejection fraction (HFpEF) in elderly women.
Therefore, better understanding of LV remodeling in
women is critical in improving the prevention of HF.
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